8-K
APTARGROUP, INC. (ATR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 27, 2023
Date of Report (Date of earliest event reported)
AptarGroup, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-11846 | 36-3853103 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014
(Address of principal executive offices)
Registrant’s telephone number, including area code: 815-477-0424.
| N/A |
|---|
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $.01 par value | ATR | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On April 27, 2023, AptarGroup, Inc. announced certain information related to its results of operations for the quarter ended March 31, 2023. The press release regarding this announcement is furnished as Exhibit 99.1 hereto.
The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| (d) Exhibits | |
|---|---|
| 99.1 | Press release issued by AptarGroup, Inc. datedApril 27, 2023. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AptarGroup, Inc. | ||
|---|---|---|
| Date: April 27, 2023 | By: | /s/ Robert W. Kuhn |
| Robert W. Kuhn | ||
| Executive Vice President and | ||
| Chief Financial Officer |
Document
Exhibit 99.1
Aptar Reports First Quarter 2023 Results
Crystal Lake, Illinois, April 27, 2023 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today reported strong operational performance driven by Aptar’s Pharma and Beauty segments. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased 4%. Aptar reported net income of $55 million for the quarter, a 12% decrease over the prior year, primarily due to restructuring charges.
“We are pleased to report a very positive start to 2023, driven by core sales growth in our Pharma and Beauty segments. Pharma results were driven by significant demand for our proprietary dispensing devices, which had core sales growth across all therapeutic indications in every region. Our robust pipeline continues to build, as we support the conversion of more drugs to nasal delivery. Sales of our beauty solutions also remained strong, especially for prestige fragrance, with growing demand in mass fragrance, color cosmetics, and sun care applications,” said Stephan B. Tanda, President and CEO, Aptar.
First Quarter 2023 Highlights
•Reported sales grew 2% and core sales increased 4% driven by demand in Pharma and Beauty
•Aptar Pharma reported sales growth of 4% and core sales growth of 7%
•Aptar Beauty reported sales growth of 6% and core sales growth of 9%
•Reported earnings per share decreased 12% to $0.82, due to restructuring charges
•Adjusted earnings per share increased 2% to $0.95
•Operating cash flow was $98 million, up from $92 million in 2022
First Quarter Results
For the quarter ended March 31, 2023, reported sales increased 2% to $860 million compared to $845 million in the prior year. Core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 4%.
| First Quarter Segment Sales Analysis<br>(Change Over Prior Year) | ||||
|---|---|---|---|---|
| Aptar<br>Pharma | Aptar<br>Beauty | Aptar<br>Closures | Total AptarGroup | |
| Reported Sales Growth | 4% | 6% | (8%) | 2% |
| Currency Effects (1) | 3% | 3% | 1% | 2% |
| Acquisitions | 0% | 0% | (1%) | 0% |
| Core Sales Growth | 7% | 9% | (8%) | 4% |
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.
Aptar Pharma’s core sales growth was driven by healthy demand for its proprietary dispensing devices used for nasal decongestants, eye care, cough and cold, and saline rinses, as well as allergic rhinitis, emergency medicines and depression therapies. Injectable core sales declined year-over-year due to a previously announced Enterprise Resource Planning (ERP) system migration, which led to reduced shipping days. However, demand for elastomeric components remained strong, including for biologics. Active materials faced a difficult comparison to the prior year quarter due to higher sales of Activ-Film™ used for at home COVID-19 test kits that did not repeat.
Aptar Beauty’s core sales growth was driven by a mix of volume and pricing. Beauty dispensing solutions, especially in prestige fragrance, as well as mass fragrance, color cosmetics and sun care drove the positive results in the quarter. Regionally, Europe and Latin America had solid growth, with North America and China showing early stages of recovery.
Core sales for the Aptar Closures segment declined compared with the prior year’s quarter due primarily to pass-throughs of lower raw material costs. Core sales in Europe and in Asia grew modestly in the quarter. Volumes in North America were lower, especially for personal care and home care closures as customers continued to work through their inventory levels, offset somewhat by improvement in food dispensing solutions.
Aptar reported first quarter earnings per share of $0.82, a decrease of 12%, compared to $0.93 reported a year ago. The decrease was primarily due to the net impact of restructuring costs year-over-year. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $0.95 and increased 2% from prior year adjusted earnings per share of $0.93, including comparable exchange rates. The prior year’s adjusted earnings included an effective tax rate of 28% (approximately $0.03 cents per share impact compared to the current year effective tax rate of 26%, which was offset by the negative impact from currency of approximately $0.03 cents).
Outlook
Regarding Aptar’s outlook, Tanda stated, “Looking to the second quarter, we anticipate our strong momentum continuing, and expect our proprietary pharma dispensing devices and beauty solutions to grow. Our injectables division’s performance should improve as the division moves past its ERP system implementation. We anticipate a gradual recovery in our Closures segment as customers, especially in North America, continue to work through their inventory. Our differentiated solutions allow us to build a robust pipeline across each of the end markets we serve, this is especially true for our proprietary pharma technologies that operate in highly regulated markets. We remain focused on driving profitable growth across each of our segments by leveraging our fixed cost base and reducing our SG&A as a percentage of sales.”
Aptar expects earnings per share for the second quarter of 2023, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.11 to $1.19. This guidance is based on an effective tax rate range of 26% to 28% which compares to an effective tax rate of 29% on prior year adjusted earnings. The earnings per share guidance range was based on a Euro/US$ exchange rate of 1.08 and the spot rates at the end of March for all other currencies. Our currency exchange rate assumptions equate to an approximately $0.02 per share tailwind when compared to the prior year second quarter earnings.
Cash Dividends and Share Repurchases
As previously announced, Aptar’s Board of Directors declared a quarterly cash dividend of $0.38 per share. The payment date is May 25, 2023, to stockholders of record as of May 4, 2023. During the first quarter, Aptar repurchased 171 thousand shares for approximately $20 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
Open Conference Call
There will be a conference call held on Friday, April 28, 2023 at 8:00 a.m. Central Time to discuss the Company’s first quarter results for 2023. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,500 dedicated employees in 20 countries. For more information, visit www.aptar.com.
Presentation of Non-GAAP Information
This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the Company's routine activities, such as restructuring and acquisition costs.
This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; the impact of COVID-19 and its variants on our global supply chain and our global customers, employees and operations, which has elevated and will continue to elevate many of the risks and uncertainties discussed below; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the execution of our restructuring initiatives; the availability of direct labor workers and the increase in direct labor costs, especially in North America; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes or difficulties in complying with government regulation; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
815-479-5530
Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income
| Three Months Ended<br><br>March 31, | |||||
|---|---|---|---|---|---|
| 2023 | 2022 | ||||
| Net Sales | $ | 860,067 | $ | 844,932 | |
| Cost of Sales (exclusive of depreciation and amortization shown below) | 557,422 | 542,728 | |||
| Selling, Research & Development and Administrative | 147,923 | 145,541 | |||
| Depreciation and Amortization | 59,259 | 58,665 | |||
| Restructuring Initiatives | 11,524 | 291 | |||
| Operating Income | 83,939 | 97,707 | |||
| Other Income (Expense): | |||||
| Interest Expense | (10,228) | (8,930) | |||
| Interest Income | 672 | 288 | |||
| Net Investment Gain (Loss) | 188 | (1,250) | |||
| Equity in Results of Affiliates | (131) | (86) | |||
| Miscellaneous, net | (1,171) | (1,103) | |||
| Income before Income Taxes | 73,269 | 86,626 | |||
| Provision for Income Taxes | 18,683 | 24,255 | |||
| Net Income | $ | 54,586 | $ | 62,371 | |
| Net Loss Attributable to Noncontrolling Interests | 178 | 52 | |||
| Net Income Attributable to AptarGroup, Inc. | $ | 54,764 | $ | 62,423 | |
| Net Income Attributable to AptarGroup, Inc. per Common Share: | |||||
| Basic | $ | 0.84 | $ | 0.95 | |
| Diluted | $ | 0.82 | $ | 0.93 | |
| Average Numbers of Shares Outstanding: | |||||
| Basic | 65,372 | 65,543 | |||
| Diluted | 66,735 | 67,146 |
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets
| March 31, 2023 | December 31, 2022 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Cash and Equivalents | $ | 126,810 | $ | 141,732 |
| Accounts and Notes Receivable, Net | 695,118 | 676,987 | ||
| Inventories | 512,687 | 486,806 | ||
| Prepaid and Other Current Assets | 146,894 | 124,766 | ||
| Total Current Assets | 1,481,509 | 1,430,291 | ||
| Property, Plant and Equipment, Net | 1,377,846 | 1,343,664 | ||
| Goodwill | 955,602 | 945,632 | ||
| Other Assets | 487,841 | 483,871 | ||
| Total Assets | $ | 4,302,798 | $ | 4,203,458 |
| LIABILITIES AND EQUITY | ||||
| Short-Term Obligations | $ | 231,464 | $ | 122,791 |
| Accounts Payable, Accrued and Other Liabilities | 809,696 | 794,385 | ||
| Total Current Liabilities | 1,041,160 | 917,176 | ||
| Long-Term Obligations | 955,918 | 1,052,597 | ||
| Deferred Liabilities and Other | 177,963 | 165,481 | ||
| Total Liabilities | 2,175,041 | 2,135,254 | ||
| AptarGroup, Inc. Stockholders' Equity | 2,112,823 | 2,053,935 | ||
| Noncontrolling Interests in Subsidiaries | 14,934 | 14,269 | ||
| Total Equity | 2,127,757 | 2,068,204 | ||
| Total Liabilities and Equity | $ | 4,302,798 | $ | 4,203,458 |
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
| Three Months Ended<br>March 31, 2023 | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consolidated | Aptar Pharma | Aptar Beauty | Aptar Closures | Corporate<br>& Other | Net Interest | |||||||||||||||||||||||||||||
| Net Sales | $ | 860,067 | $ | 356,046 | $ | 326,389 | $ | 177,632 | $ | — | $ | — | ||||||||||||||||||||||
| Reported net income | $ | 54,586 | ||||||||||||||||||||||||||||||||
| Reported income taxes | 18,683 | |||||||||||||||||||||||||||||||||
| Reported income before income taxes | 73,269 | 82,390 | 7,432 | 13,295 | (20,292) | (9,556) | ||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||
| Restructuring initiatives | 11,524 | 1,131 | 9,291 | 522 | 580 | |||||||||||||||||||||||||||||
| Net unrealized investment gain | (188) | — | — | — | (188) | |||||||||||||||||||||||||||||
| Transaction costs related to acquisitions | 255 | — | 199 | 56 | — | |||||||||||||||||||||||||||||
| Adjusted earnings before income taxes | 84,860 | 83,521 | 16,922 | 13,873 | (19,900) | (9,556) | ||||||||||||||||||||||||||||
| Interest expense | 10,228 | 10,228 | ||||||||||||||||||||||||||||||||
| Interest income | (672) | (672) | ||||||||||||||||||||||||||||||||
| Adjusted earnings before net interest and taxes (Adjusted EBIT) | 94,416 | 83,521 | 16,922 | 13,873 | (19,900) | — | ||||||||||||||||||||||||||||
| Depreciation and amortization | 59,259 | 25,777 | 20,283 | 12,135 | 1,064 | |||||||||||||||||||||||||||||
| Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 153,675 | $ | 109,298 | $ | 37,205 | $ | 26,008 | $ | (18,836) | $ | — | ||||||||||||||||||||||
| Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 17.9 | % | 30.7 | % | 11.4 | % | 14.6 | % | Three Months Ended<br>March 31, 2022 | |||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||||||||||||||||
| Consolidated | Aptar Pharma | Aptar Beauty | Aptar Closures | Corporate<br>& Other | Net Interest | |||||||||||||||||||||||||||||
| Net Sales | $ | 844,932 | $ | 342,462 | $ | 309,080 | $ | 193,390 | $ | — | $ | — | ||||||||||||||||||||||
| Reported net income | $ | 62,371 | ||||||||||||||||||||||||||||||||
| Reported income taxes | 24,255 | |||||||||||||||||||||||||||||||||
| Reported income before income taxes | 86,626 | 92,206 | 14,008 | 10,646 | (21,592) | (8,642) | ||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||
| Restructuring initiatives | 291 | — | 111 | 180 | — | |||||||||||||||||||||||||||||
| Net unrealized investment loss | 2,091 | — | — | — | 2,091 | |||||||||||||||||||||||||||||
| Adjusted earnings before income taxes | 89,008 | 92,206 | 14,119 | 10,826 | (19,501) | (8,642) | ||||||||||||||||||||||||||||
| Interest expense | 8,930 | 8,930 | ||||||||||||||||||||||||||||||||
| Interest income | (288) | (288) | ||||||||||||||||||||||||||||||||
| Adjusted earnings before net interest and taxes (Adjusted EBIT) | 97,650 | 92,206 | 14,119 | 10,826 | (19,501) | — | ||||||||||||||||||||||||||||
| Depreciation and amortization | 58,665 | 23,346 | 20,431 | 13,357 | 1,531 | — | ||||||||||||||||||||||||||||
| Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 156,315 | $ | 115,552 | $ | 34,550 | $ | 24,183 | $ | (17,970) | $ | — | ||||||||||||||||||||||
| Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 18.5 | % | 33.7 | % | 11.2 | % | 12.5 | % |
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
| Three Months Ended<br>March 31, | |||||
|---|---|---|---|---|---|
| 2023 | 2022 | ||||
| Income before Income Taxes | $ | 73,269 | $ | 86,626 | |
| Adjustments: | |||||
| Restructuring initiatives | 11,524 | 291 | |||
| Net unrealized investment (gain) loss | (188) | 2,091 | |||
| Transaction costs related to acquisitions | 255 | — | |||
| Foreign currency effects (1) | (2,393) | ||||
| Adjusted Earnings before Income Taxes | $ | 84,860 | $ | 86,615 | |
| Provision for Income Taxes | $ | 18,683 | $ | 24,255 | |
| Adjustments: | |||||
| Restructuring initiatives | 3,065 | 77 | |||
| Net unrealized investment (gain) loss | (46) | 512 | |||
| Transaction costs related to acquisitions | 65 | — | |||
| Foreign currency effects (1) | (670) | ||||
| Adjusted Provision for Income Taxes | $ | 21,767 | $ | 24,174 | |
| Net (Income) Loss Attributable to Noncontrolling Interests | $ | 178 | $ | 52 | |
| Net Income Attributable to AptarGroup, Inc. | $ | 54,764 | $ | 62,423 | |
| Adjustments: | |||||
| Restructuring initiatives | 8,459 | 214 | |||
| Net unrealized investment (gain) loss | (142) | 1,579 | |||
| Transaction costs related to acquisitions | 190 | — | |||
| Foreign currency effects (1) | (1,723) | ||||
| Adjusted Net Income Attributable to AptarGroup, Inc. | $ | 63,271 | $ | 62,493 | |
| Average Number of Diluted Shares Outstanding | 66,735 | 67,146 | |||
| Net Income Attributable to AptarGroup, Inc. Per Diluted Share | $ | 0.82 | $ | 0.93 | |
| Adjustments: | |||||
| Restructuring initiatives | 0.13 | — | |||
| Net unrealized investment (gain) loss | — | 0.03 | |||
| Transaction costs related to acquisitions | — | — | |||
| Foreign currency effects (1) | (0.03) | ||||
| Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share | $ | 0.95 | $ | 0.93 |
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.
AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands)
| Three Months Ended<br>March 31, | |||||
|---|---|---|---|---|---|
| 2023 | 2022 | ||||
| Net Cash Provided by Operations | $ | 98,304 | $ | 92,077 | |
| Capital Expenditures | (77,825) | (73,058) | |||
| Proceeds from Government Grants | — | 7,955 | |||
| Free Cash Flow | $ | 20,479 | $ | 26,974 |
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
| Three Months Ending<br>June 30, | |||
|---|---|---|---|
| Expected 2023 | 2022 | ||
| Income before Income Taxes | $ | 89,471 | |
| Adjustments: | |||
| Restructuring initiatives | 428 | ||
| Net unrealized investment loss | 483 | ||
| Transaction costs related to acquisitions | — | ||
| Foreign currency effects (1) | 1,564 | ||
| Adjusted Earnings before Income Taxes | $ | 91,946 | |
| Provision for Income Taxes | $ | 25,858 | |
| Adjustments: | |||
| Restructuring initiatives | 111 | ||
| Net unrealized investment loss | 119 | ||
| Transaction costs related to acquisitions | — | ||
| Foreign currency effects (1) | 452 | ||
| Adjusted Provision for Income Taxes | $ | 26,540 | |
| Net Loss Attributable to Noncontrolling Interests | $ | 12 | |
| Net Income Attributable to AptarGroup, Inc. | $ | 63,625 | |
| Adjustments: | |||
| Restructuring initiatives | 317 | ||
| Net unrealized investment loss | 364 | ||
| Transaction costs related to acquisitions | — | ||
| Foreign currency effects (1) | 1,112 | ||
| Adjusted Net Income Attributable to AptarGroup, Inc. | $ | 65,418 | |
| Average Number of Diluted Shares Outstanding | 66,900 | ||
| Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) | $ | 0.95 | |
| Adjustments: | |||
| Restructuring initiatives | — | ||
| Net unrealized investment loss | 0.01 | ||
| Transaction costs related to acquisitions | — | ||
| Foreign currency effects (1) | 0.02 | ||
| Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) | $1.11 - $1.19 | $ | 0.98 |
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using a Euro/US$ exchange rate of 1.08 and the spot rates as of March 31, 2023 for all other applicable foreign currency exchange rates.
(2) AptarGroup’s expected earnings per share range for the second quarter of 2023, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 26.0% to 28.0%. This tax rate range compares to our second quarter of 2022 effective tax rate of 29% on reported and adjusted earnings per share.
10